Your browser doesn't support javascript.
loading
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.
Horn, Thomas; Ferretti, Stéphane; Ebel, Nicolas; Tam, Angela; Ho, Samuel; Harbinski, Fred; Farsidjani, Ali; Zubrowski, Matthew; Sellers, William R; Schlegel, Robert; Porter, Dale; Morris, Erick; Wuerthner, Jens; Jeay, Sébastien; Greshock, Joel; Halilovic, Ensar; Garraway, Levi A; Caponigro, Giordano; Lehár, Joseph.
Afiliação
  • Horn T; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Ferretti S; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Ebel N; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Tam A; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Ho S; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Harbinski F; Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Farsidjani A; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Zubrowski M; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Sellers WR; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Schlegel R; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Porter D; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Morris E; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Wuerthner J; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Jeay S; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Greshock J; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Halilovic E; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Garraway LA; Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts.
  • Caponigro G; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts. giordano.caponigro@novartis.com lehar@google.com.
  • Lehár J; Translational Clinical Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts. giordano.caponigro@novartis.com lehar@google.com.
Cancer Res ; 76(23): 6950-6963, 2016 12 01.
Article em En | MEDLINE | ID: mdl-27659046
ABSTRACT
Like classical chemotherapy regimens used to treat cancer, targeted therapies will also rely upon polypharmacology, but tools are still lacking to predict which combinations of molecularly targeted drugs may be most efficacious. In this study, we used image-based proliferation and apoptosis assays in colorectal cancer cell lines to systematically investigate the efficacy of combinations of two to six drugs that target critical oncogenic pathways. Drug pairs targeting key signaling pathways resulted in synergies across a broad spectrum of genetic backgrounds but often yielded only cytostatic responses. Enhanced cytotoxicity was observed when additional processes including apoptosis and cell cycle were targeted as part of the combination. In some cases, where cell lines were resistant to paired and tripled drugs, increased expression of antiapoptotic proteins was observed, requiring a fourth-order combination to induce cytotoxicity. Our results illustrate how high-order drug combinations are needed to kill drug-resistant cancer cells, and they also show how systematic drug combination screening together with a molecular understanding of drug responses may help define optimal cocktails to overcome aggressive cancers. Cancer Res; 76(23); 6950-63. ©2016 AACR.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2016 Tipo de documento: Article